Stockscreener 앱 받기
51.63
2.70%
-1.43
시간 외 거래:
51.63
전일 마감가:
$53.06
열려 있는:
$52.91
하루 거래량:
1.98M
Relative Volume:
0.79
시가총액:
$9.72B
수익:
$2.69B
순이익/손실:
$-214.04M
주가수익비율:
-44.13
EPS:
-1.17
순현금흐름:
$98.43M
1주 성능:
+0.16%
1개월 성능:
+13.47%
6개월 성능:
+0.29%
1년 성능:
-4.65%
1일 변동 폭
$51.58
$53.67
1주일 범위
$50.72
$54.49
52주 변동 폭
$39.97
$72.83
이그젝트 사이 Stock (EXAS) Company Profile
명칭
Exact Sciences Corp
전화
608-284-5700
주소
5505 ENDEAVOR LANE, MADISON, WI
EXAS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
51.63 | 9.72B | 2.69B | -214.04M | 98.43M | -1.17 |
|
TMO
Thermo Fisher Scientific Inc
|
403.13 | 159.89B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.73 | 142.45B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
491.70 | 37.95B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
106.93 | 30.97B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
148.99 | 26.72B | 15.50B | 1.33B | 2.16B | 7.34 |
이그젝트 사이 Stock (EXAS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-27 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-01-02 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-10-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-08-02 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-05-10 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2023-05-05 | 개시 | UBS | Neutral |
| 2023-03-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-02-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-06-03 | 개시 | Piper Sandler | Neutral |
| 2021-11-03 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | 재확인 | BTIG Research | Buy |
| 2021-07-29 | 재확인 | Canaccord Genuity | Buy |
| 2021-07-29 | 재확인 | Oppenheimer | Outperform |
| 2021-07-29 | 재확인 | Stifel | Buy |
| 2021-06-15 | 개시 | Raymond James | Strong Buy |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-05-25 | 개시 | Wells Fargo | Equal Weight |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-10-29 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-10-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-08 | 재개 | BTIG Research | Buy |
| 2020-04-02 | 개시 | Evercore ISI | Outperform |
| 2020-01-10 | 재개 | BTIG Research | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Dougherty & Company | Buy |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-10-17 | 재확인 | BofA/Merrill | Buy |
| 2019-10-01 | 재개 | Craig Hallum | Buy |
| 2019-09-26 | 개시 | Oppenheimer | Outperform |
| 2019-02-26 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-09 | 개시 | UBS | Buy |
| 2018-09-05 | 재개 | The Benchmark Company | Hold |
| 2018-08-13 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2018-01-29 | 개시 | Goldman | Neutral |
| 2018-01-08 | 재확인 | The Benchmark Company | Buy |
| 2017-11-13 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | 다운그레이드 | BTIG Research | Buy → Neutral |
모두보기
이그젝트 사이 주식(EXAS)의 최신 뉴스
Analysts Have Made A Financial Statement On Exact Sciences Corporation's (NASDAQ:EXAS) First-Quarter Report - Yahoo
Exact Sciences Corporation (NASDAQ:EXAS) Q1 2025 Earnings Call Transcript - Insider Monkey
Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight - GuruFocus
Exact Sciences Corp Reports Strong Start to 2025 - TipRanks
Exact Sciences (EXAS) Target Price Raised by Barclays to $75 | EXAS Stock News - GuruFocus
Exact Sciences (EXAS) Price Target Raised by RBC Capital | EXAS Stock News - GuruFocus
Exact Sciences: Q1 Earnings Snapshot - GMToday.com
Lobbying Update: $470,000 of EXACT SCIENCES lobbying was just disclosed - Nasdaq
Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect - Barchart.com
Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday - Benzinga
Exact Sciences (EXAS) Sees Target Price Raised by Baird | EXAS S - GuruFocus
EXAS: Evercore ISI Group Raises Price Target for Exact Sciences - GuruFocus
EXAS: Evercore ISI Group Raises Price Target for Exact Sciences | EXAS Stock News - GuruFocus
Exact Sciences (EXAS) Sees Target Price Raised by Baird | EXAS Stock News - GuruFocus
Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance - Benzinga
Exact Sciences (EXAS) Price Target Raised to $72 by Baird Analys - GuruFocus
RBC Raises Price Target on Exact Sciences to $54 From $52, Keeps Sector Perform Rating - marketscreener.com
Exact Sciences (EXAS) Price Target Raised to $72 by Baird Analyst | EXAS Stock News - GuruFocus
S&P 500 Futures Rise in Premarket Trading; McCormick Vtg, Exact Sciences Lead - Barron's
Exact Sciences to Participate in May Investor Conference | EXAS Stock News - GuruFocus
Barclays Elevates Price Target for Exact Sciences (EXAS) to $75 - GuruFocus
Exact Sciences to Participate in May Investor Conference - Business Wire
Barclays Elevates Price Target for Exact Sciences (EXAS) to $75 | EXAS Stock News - GuruFocus
Exact Sciences Corp (EXAS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and New ... - Yahoo Finance
Exact Sciences Corp (EXAS) Q1 2025 Earnings Call Highlights: Str - GuruFocus
Exact Sciences reports Q1 EPS (54c) vs (60c) last year - TipRanks
Exact Sciences Reports Strong Q1 2025 Results - TipRanks
Exact Sciences Q1 2025 slides: revenue growth accelerates, profitability improves By Investing.com - Investing.com South Africa
Exact Sciences (EXAS) Boosts Revenue Outlook; Shares Rise Post-M - GuruFocus
Exact Sciences Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Exact Sciences Corp (EXAS) Q1 2025 Earnings: Revenue Surpasses E - GuruFocus
Exact Sciences Announces First-Quarter 2025 Results | EXAS Stock News - GuruFocus
Exact Sciences (EXAS) Surpasses Q1 2025 Expectations with 11% Re - GuruFocus
EXACT Sciences earnings missed by $0.21, revenue topped estimates - Investing.com South Africa
Exact Sciences Q1 2025 slides: revenue growth accelerates, profitability improves - Investing.com
Earnings call transcript: Exact Sciences Q1 2025 sees revenue growth, stock surges - Investing.com
Exact Sciences Q1 Adjusted Loss Narrows, Revenue Rises; Shares Up - marketscreener.com
Exact Sciences stock surges 8% on Q1 revenue beat, raised guidance By Investing.com - Investing.com South Africa
Exact Sciences stock surges 8% on Q1 revenue beat, raised guidance - Investing.com Australia
EXACT SCIENCES CORP SEC 10-Q Report - TradingView
Exact Sciences (EXAS) Q1 Revenue Beats Expectations, Raises Full-Year Outlook | EXAS Stock News - GuruFocus
Earnings Flash (EXAS) Exact Sciences Posts Q1 Revenue $706.8M, vs. FactSet Est of $688.6M - marketscreener.com
Exact Sciences Crushes Q1 Earnings: Revenue Surges 11%, Launches Revolutionary Cancer Detection Tests - Stock Titan
Global Molecular Diagnostics Market to Expand at a CAGR of ~9% by 2032 Due to the Rising Demand for Precision Medicine | DelveInsight - GlobeNewswire Inc.
Exact Sciences reports Q1 results that top analysts’ expectations - Wisconsin State Journal
Exact Sciences (EXAS) Reports Q1: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Exact Sciences appoints new board member - Investing.com
Form DEF 14A EXACT SCIENCES CORP For: Jun 12 - StreetInsider
Exact Sciences to Highlight Cologuard® Test Adherence and Predic - GuruFocus
Exact Sciences to Highlight Cologuard Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025 - Business Wire
This Exact Sciences Insider Increased Their Holding In The Last Year - Yahoo Finance
이그젝트 사이 (EXAS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.60%
1.22%
자본화:
|
볼륨(24시간):